Sorin received CE mark approval for its Mitroflow aortic pericardial heart valve. This novel valve contains a proprietary advanced tissue with phospholipid reduction properties which is intended to prevent the potential calcification of the Mitroflow bioprosthetic valve. Research has demonstrated that phospholipids play a key role in the calcification process of biosprotheses.
Phospholipid reduction treatment has been shown to decrease phospholipid content in the pericardial tissue, which leads to a reduction of up to 99% of calcium uptake in the treated pericardial tissue.
“We trust the proven excellent performance of our bioprosthesis and we are pleased to provide patients and cardiothoracic surgeons with Mitroflow with phopholipid reduction treatment which will potentially lead to further enhancing the valve’s proven long-term performance,” said Davide Bianchi, president Heart Valve Business Unit, Sorin Group.